Abruptly stopping the drugs following high-dose treatment can cause withdrawal symptoms such as fatigue and depression
Ozempic is a GLP-1 receptor agonist, while Mounjaro is a dual GLP-1/GIP agonist
Hims is not like Ozempic because Hims is a telehealth platform, not a medication
DOI.org (Crossref) , Mehrtash, Farhad, et al
As demonstrated in this study, short-acting GLP-1RAs, such as lixisenatide, were associated with a significantly higher risk of nausea and vomiting compared to long-acting and ultra-long-acting GLP-1RAs, such as dulaglutide and semaglutide
Ozempic has gained in popularity due to off-label use, meaning its use for conditions not directly tested in a clinical trial or not approved by the FDA